Aortic valve stenosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 22 Jun 2026 04:02:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Aortic valve stenosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis https://clinicaltrials.eu/trial/study-of-ataciguat-to-slow-progression-of-moderate-calcific-aortic-valve-stenosis-in-adults/ Wed, 17 Jun 2026 04:03:04 +0000 https://clinicaltrials.eu/trial/study-of-ataciguat-to-slow-progression-of-moderate-calcific-aortic-valve-stenosis-in-adults/ People with Moderate Calcific Aortic Valve Stenosis have a heart valve that becomes thick and stiff, making it harder for blood to flow from the heart to the rest of the body. The study is testing an oral medication called Ataciguat, which is taken as a capsule each day, and comparing it with a placebo that looks the same but contains no active drug.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

]]> Study of Colchicine Treatment to Slow Down Aortic Valve Stenosis Progression in Adult Patients with Moderate Disease https://clinicaltrials.eu/trial/study-on-colchicine-for-slowing-aortic-valve-stenosis-in-patients-with-moderate-aortic-stenosis/ Wed, 29 Apr 2026 15:02:11 +0000 https://clinicaltrials.eu/trial/study-on-colchicine-for-slowing-aortic-valve-stenosis-in-patients-with-moderate-aortic-stenosis/ This study focuses on patients with Aortic Valve Stenosis, a heart condition where the aortic valve becomes narrow and stiff due to calcium buildup, making it harder for blood to flow from the heart to the rest of the body. The study will test whether colchicine, a medication given as tablets, can slow down the progression of this condition compared to placebo.

The purpose of the study is to determine if colchicine treatment can reduce the progression of moderate aortic valve stenosis by decreasing inflammation and calcium buildup in the heart valve. Participants in this study will receive either colchicine tablets or placebo tablets for approximately 24 months.

The study will use various imaging techniques to monitor changes in the heart valve over time, including computed tomography scans to measure calcium buildup, echocardiography (ultrasound of the heart) to assess blood flow through the valve, and positron emission tomography to evaluate valve activity. The study is designed so that neither the participants nor the researchers will know who is receiving which treatment.

]]> Study on Icosapent Ethyl for Slowing Aortic Valve Stenosis Progression in Patients with Aortic Valve Stenosis https://clinicaltrials.eu/trial/study-on-icosapent-ethyl-for-slowing-aortic-valve-stenosis-progression-in-patients-with-aortic-valve-stenosis/ Wed, 29 Apr 2026 14:59:01 +0000 https://clinicaltrials.eu/trial/study-on-icosapent-ethyl-for-slowing-aortic-valve-stenosis-progression-in-patients-with-aortic-valve-stenosis/ This clinical trial is focused on studying the effects of a medication called icosapent ethyl on a condition known as aortic valve stenosis. Aortic valve stenosis is a heart condition where the valve between the heart and the main blood vessel to the body becomes narrowed, making it harder for the heart to pump blood. The medication being tested, icosapent ethyl, is provided in the form of soft capsules known as Vazkepa 998 mg soft capsules. The purpose of the study is to see if icosapent ethyl can slow down the progression of calcification, which is the buildup of calcium, in the aortic valve.

Participants in the study will take the medication orally, which means it is swallowed. The study will last for a period of 24 months, during which time the effects of the medication on the aortic valve will be monitored. This includes looking at changes in the amount of calcium in the valve, as well as other factors like the speed of blood flow through the valve and the size of the valve opening. The study will also examine changes in the volume of plaque, which is a buildup of substances in the arteries, in the heart’s blood vessels.

The trial aims to provide valuable information on whether icosapent ethyl can help manage aortic valve stenosis by slowing down the calcification process. This could potentially lead to new treatment options for individuals with this heart condition. Participants will be monitored throughout the study to ensure their safety and to gather data on the medication’s effectiveness.

]]> Study on Short vs. Long Antiplatelet Therapy with Aspirin for Adults After TAVI for Symptomatic Aortic Stenosis https://clinicaltrials.eu/trial/study-on-short-vs-long-antiplatelet-therapy-with-aspirin-for-adults-after-tavi-for-symptomatic-aortic-stenosis/ Wed, 29 Apr 2026 14:56:14 +0000 https://clinicaltrials.eu/trial/study-on-short-vs-long-antiplatelet-therapy-with-aspirin-for-adults-after-tavi-for-symptomatic-aortic-stenosis/ This clinical trial is focused on patients who have undergone a procedure called transcatheter aortic valve implantation (TAVI) to treat a condition known as aortic stenosis. Aortic stenosis is a narrowing of the heart’s aortic valve, which can lead to symptoms like chest pain, fatigue, and shortness of breath. The study is comparing two different durations of treatment with aspirin, a common medication used to prevent blood clots. The two forms of aspirin being studied are KARDEGIC 75 mg, which is a powder for oral solution, and ASPIRINE PROTECT 100 mg, which is a gastro-resistant tablet. Both medications are taken by mouth.

The purpose of the study is to determine if a shorter duration of aspirin therapy, lasting 3 months, is as effective as the standard 12-month therapy in preventing certain health events after the TAVI procedure. These health events include things like heart attacks, strokes, and significant bleeding. Participants in the study will be randomly assigned to either the short-term or long-term aspirin therapy group. The study will follow participants for 12 months to monitor their health and any events that occur.

Throughout the study, participants will receive regular check-ups to assess their health and any side effects from the treatment. The study aims to provide valuable information on the optimal duration of aspirin therapy for patients who have undergone TAVI, potentially improving treatment guidelines and patient outcomes in the future.

]]> Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients https://clinicaltrials.eu/trial/study-on-pelacarsen-for-slowing-calcific-aortic-valve-stenosis-in-patients/ Wed, 29 Apr 2026 14:29:03 +0000 https://clinicaltrials.eu/trial/study-on-pelacarsen-for-slowing-calcific-aortic-valve-stenosis-in-patients/ This clinical trial is focused on studying the effects of a treatment for Calcific Aortic Valve Stenosis, a condition where the heart’s aortic valve becomes narrowed due to calcium buildup, making it harder for the heart to pump blood. The treatment being tested is called pelacarsen, also known by its code name TQJ230. Pelacarsen is an antisense oligonucleotide, which is a type of medication designed to lower levels of a specific protein in the blood called lipoprotein(a). This protein is linked to the progression of the disease.

The purpose of the study is to see if pelacarsen can slow down the worsening of calcific aortic valve stenosis. Participants in the study will receive either pelacarsen or a placebo, which looks like the treatment but does not contain the active medication. The study will last for about 36 months, during which participants will receive regular injections of the treatment or placebo. The effects of the treatment will be monitored through various tests, including echocardiography, which uses sound waves to create images of the heart, and computed tomography (CT), a type of imaging that provides detailed pictures of the heart’s structure.

Throughout the study, changes in the heart’s function and structure will be assessed to determine if pelacarsen is effective in slowing the disease’s progression. Participants will also have their lipoprotein(a) levels checked, and any side effects or health changes will be closely monitored to ensure safety. The study aims to provide valuable information on whether pelacarsen can be a beneficial treatment for people with calcific aortic valve stenosis.

]]> Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI https://clinicaltrials.eu/trial/study-on-personalized-antithrombotic-therapy-with-acenocoumarol-phenprocoumon-and-apixaban-for-patients-with-aortic-valve-stenosis-post-tavi/ Wed, 29 Apr 2026 14:26:07 +0000 https://clinicaltrials.eu/trial/study-on-personalized-antithrombotic-therapy-with-acenocoumarol-phenprocoumon-and-apixaban-for-patients-with-aortic-valve-stenosis-post-tavi/ This clinical trial is focused on patients with aortic valve stenosis, a condition where the valve between the heart and the main artery becomes narrowed, affecting blood flow. The study aims to compare two different approaches to prevent blood clots and bleeding after a procedure called transcatheter aortic valve implantation (TAVI). One approach uses a personalized treatment plan guided by computed tomography (CT) scans, while the other uses a standard lifelong single antiplatelet therapy. Antiplatelet therapy involves medications that help prevent blood cells called platelets from clumping together to form clots.

The medications being studied include Acenocoumarol, Fenprocoumon, Prasugrel, Apixaban, Clopidogrel, Warfarin, Ticagrelor, and Acetylsalicylic Acid (commonly known as aspirin). Some participants will receive these medications, while others may receive a placebo. The purpose of the study is to determine if the personalized treatment plan is more effective in reducing the risk of heart-related deaths, blood clots, and bleeding events compared to the standard treatment.

Participants in the study will be randomly assigned to one of the two treatment groups. They will be monitored over time to assess the occurrence of any heart-related events, blood clots, or bleeding. The study will also evaluate the overall health and quality of life of participants, as well as their adherence to the medication regimen. The trial is expected to continue until 2027, with regular follow-ups to gather comprehensive data on the effectiveness and safety of the treatments being tested.

]]> Study on Blood Thinners Apixaban, Edoxaban, Rivaroxaban, and Acetylsalicylic Acid for Patients with Aortic Stenosis After Heart Valve Replacement https://clinicaltrials.eu/trial/study-on-blood-thinners-apixaban-edoxaban-rivaroxaban-and-acetylsalicylic-acid-for-patients-with-aortic-stenosis-after-heart-valve-replacement/ Wed, 29 Apr 2026 14:22:45 +0000 https://clinicaltrials.eu/trial/study-on-blood-thinners-apixaban-edoxaban-rivaroxaban-and-acetylsalicylic-acid-for-patients-with-aortic-stenosis-after-heart-valve-replacement/ This clinical trial is focused on patients with aortic stenosis, a condition where the heart’s aortic valve narrows, affecting blood flow. The study aims to find the best blood-thinning treatment after patients undergo a procedure called transcatheter aortic valve implantation (TAVI), which involves placing a new valve in the heart without open-heart surgery. The treatments being studied include medications known as anticoagulants and acetylsalicylic acid, commonly known as aspirin. The anticoagulants being tested are apixaban, edoxaban, and rivaroxaban. These medications help prevent blood clots, which can be a concern after heart valve procedures.

The purpose of the study is to determine the most effective and safe treatment strategy for preventing complications such as blood clots and bleeding after TAVI. Participants in the study will be randomly assigned to receive either one of the anticoagulants or acetylsalicylic acid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for up to 12 months, during which participants will take the assigned medication and attend regular follow-up visits to monitor their health and any side effects.

Throughout the study, researchers will closely observe the participants to assess the effectiveness of the treatments in preventing complications and improving overall health outcomes. The study will also evaluate the safety of these medications by monitoring for any adverse effects, such as bleeding or other health issues. The findings from this trial will help doctors make informed decisions about the best treatment options for patients with aortic stenosis who undergo TAVI.

]]>